The Chromosomal Microarray Analysis (CMA) Testing Market size was valued at USD 1.2 Billion in 2022 and is projected to reach USD 2.5 Billion by 2030, growing at a CAGR of 10.1% from 2024 to 2030.

The identification of clinically relevant genomic dosage anomalies assists in accurate diagnosis, prognosis, and medical management of affected individuals. Technological advancements within the field ...

Current serological immunoassays have inherent limitations for certain infectious diseases such as Lyme disease, a bacterial infection caused by Borrelia burgdorferi in North America. Here we report a ...

The Europe Chromosomal Microarray (Cma) Testing Market, valued at 9.28 billion in 2025, is anticipated to advance at a CAGR of 13.33% during 2026–2033, reaching 19.66 billion by 2033 as adoption grows ...

JA Rosenfeld is an employee of Signature Genomic Laboratories, a subsidiary of PerkinElmer, Inc. The authors have no other relevant affiliations or financial involvement with any organization or ...

An international consortium of genetics experts has issued a consensus statement recommending chromosomal microarray (CMA) as the new standard practice for genetic evaluation of children with ...

JA Rosenfeld is an employee of Signature Genomic Laboratories, a subsidiary of PerkinElmer, Inc. The authors have no other relevant affiliations or financial involvement with any organization or ...

CombiMatrix, a CLIA-certified laboratory, is bringing microarray analysis to the underserved problem of recurrent pregnancy loss as well as to prenatal testing. CombiMatrix performs microarray assays ...

An international consortium of genetics experts has issued a consensus statement recommending chromosomal microarray (CMA) as the new standard practice for genetic evaluation of children with ...

An international consortium of genetics experts has issued a consensus statement recommending chromosomal microarray as the new standard practice for genetic evaluation of children with unexplained ...

A new method of prenatal testing that can detect more genetic problems in a fetus than ever before could be headed toward wider use after encouraging results from a clinical trial, researchers said.

At CombiMatrix Corp., a diagnostic laboratory in Irvine, white-cloaked techs sit hunched over microscopes while their gloved hands deftly pick through the remains of lost pregnancies, pulling the ...